Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a selective aldosterone synthase inhibitor targeting treatment-resistant and uncontrolled hypertension. The company's lead asset completed Phase 2 TARGET-HTN trial demonstrating statistically significant blood pressure reductions in patients with uncontrolled hypertension, positioning it for Phase 3 development. With zero revenue, $200M annual cash burn, and 25.5x current ratio indicating substantial cash runway, MLYS represents a binary clinical-stage bet on a novel mechanism addressing a large underserved hypertension market estimated at 15-20 million US patients with resistant hypertension.
Mineralys operates a classic biotech development model: raise capital through equity offerings, invest in clinical trials to generate safety/efficacy data, obtain FDA approval, then commercialize or partner. Lorundrostat targets aldosterone synthase (CYP11B2) selectively versus older non-selective agents, potentially offering superior safety profile. The company's value proposition rests on addressing treatment-resistant hypertension where existing therapies (ACE inhibitors, ARBs, diuretics, calcium channel blockers) fail to control blood pressure in 15-20% of hypertensive patients. Pricing power would derive from novel mechanism, differentiated safety, and addressing high unmet need in cardiovascular risk reduction. Commercial strategy likely involves either building specialized cardiovascular sales force or partnering with larger pharmaceutical company for commercialization.
Phase 3 trial design announcements and FDA alignment on registration pathway for lorundrostat
Clinical data readouts showing blood pressure reduction magnitude, durability, and safety versus standard of care
FDA regulatory milestones including IND clearances, breakthrough therapy designation potential, and NDA submission timing
Partnership announcements or licensing deals that validate lorundrostat's commercial potential and provide non-dilutive funding
Equity financing announcements and terms (dilution concerns versus runway extension)
Competitive developments in resistant hypertension space including Bayer's finerenone, Idorsia's aprocitentan
Binary clinical risk: Phase 3 failure would likely render equity worthless. Cardiovascular outcomes trials require large patient populations (1000+ patients), multi-year duration, and have historically high failure rates even after positive Phase 2 results
FDA regulatory pathway uncertainty for novel mechanism. Aldosterone synthase inhibition is unproven class; agency may require cardiovascular outcomes data beyond blood pressure reduction, significantly extending timeline and capital requirements
Reimbursement risk: Payers increasingly scrutinizing hypertension therapies given availability of low-cost generics. Lorundrostat would need to demonstrate compelling outcomes benefit or cost-effectiveness in resistant population to achieve favorable formulary positioning
Crowded resistant hypertension pipeline including Idorsia's aprocitentan (endothelin receptor antagonist, already approved in EU), Bayer's finerenone (non-steroidal mineralocorticoid receptor antagonist with cardiovascular outcomes data), and multiple device-based approaches (renal denervation)
Mechanism-of-action risk: Selective aldosterone synthase inhibition unproven in large outcomes trials. Non-selective agents showed safety concerns historically. If lorundrostat demonstrates similar issues at scale, validates competitive approaches
Standard of care evolution: SGLT2 inhibitors and GLP-1 agonists showing cardiovascular benefits may reduce resistant hypertension population or raise bar for incremental benefit demonstration
Equity dilution risk: Company will require $300-500M additional capital to fund Phase 3 program through NDA submission. At current $1.9B market cap, this represents 15-25% dilution assuming reasonable financing terms. Worse terms in adverse market conditions could be significantly more dilutive
Cash runway management: With $200M annual burn and acceleration expected for Phase 3, company has approximately 3-4 year runway. Mistimed financing or clinical delays could force distressed capital raise
No debt cushion: While zero debt reduces financial risk, also means no non-dilutive capital source available. Pure equity dependency increases shareholder dilution risk versus peers with credit facilities
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations. R&D spending follows scientific timelines rather than economic cycles. However, capital markets access for financing is cyclically sensitive. During recessions or risk-off periods, biotech IPO/follow-on markets can freeze, creating refinancing risk for cash-burning companies. Patient enrollment in trials generally unaffected by economic conditions given chronic disease focus.
Rising interest rates negatively impact MLYS through two channels: (1) Valuation compression - pre-revenue biotechs are valued on discounted future cash flows 5-10 years out, making them highly duration-sensitive. Higher discount rates significantly reduce NPV of potential approval scenarios. (2) Opportunity cost - as risk-free rates rise, speculative biotech investments become less attractive versus safer alternatives, reducing investor appetite for clinical-stage names. The company's cash balance earns higher yields in rising rate environment (modest positive), but this is overwhelmed by valuation multiple compression. Current negative cash flow means no benefit from operational leverage to rates.
Minimal direct credit exposure. Company has zero debt (0.00 D/E ratio) and operates on equity financing model. No credit facility dependence or refinancing risk. Indirectly, tighter credit conditions reduce biotech sector liquidity and M&A activity, potentially limiting exit options or partnership opportunities. Pharmaceutical acquirers may face higher cost of capital for M&A financing in tight credit environments, reducing takeout premiums.
growth/speculative - Attracts biotech-specialized investors, hedge funds with event-driven strategies around clinical catalysts, and retail momentum traders. The 191% one-year return and -36.9% three-month return demonstrate extreme volatility typical of binary clinical-stage names. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. Institutional ownership likely concentrated among healthcare-focused funds with expertise evaluating clinical risk/reward. The recent 92.4% six-month return followed by sharp pullback suggests momentum-driven trading around clinical updates.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions). Single-asset companies like MLYS particularly volatile as entire equity value depends on lorundrostat success. Recent performance shows 191% annual gain but -36.9% three-month decline, demonstrating 50%+ intraday moves possible on news. Implied volatility likely 80-100%+ range. Beta to broader market low during risk-on periods (company-specific drivers dominate), but correlates strongly during risk-off selloffs when speculative growth names sold indiscriminately. Options market likely active around known catalyst dates.
